Immunotherapy with immune checkpoint inhibitors (ICIs) nowadays has indications for
several solid tumors. The current targets for ICIs are CTLA-4, PD-1, and PD-L1 receptors …

Immune checkpoint inhibitors (ICIs) are a class of drug that produces durable and sustained
anti-tumour responses in a wide variety of malignancies. The exponential rise in their use …

Immune checkpoint inhibitor therapy for cancer treatment can give rise to a variety of
adverse events. Here we report a male patient with metastatic melanoma who experienced …

PD-1 inhibitors, as one of commonly used immune checkpoint inhibitors, enable T-cell
activation and prevent immune escape by blocking the PD-1/PD-L1 signaling pathway. They …

Background Immune checkpoint inhibitor (ICI) therapy can be complicated by
gastrointestinal adverse events (AEs). Similarly, gastrointestinal AEs have been reported …

Simple Summary Immunotherapy is an effective cancer treatment that activates the immune
system to target and destroy cancer cells. The emerging use of a form of immunotherapy …

Background We investigated the clinical and endoscopic features, management strategies,
and outcomes of Chinese cancer patients with immune checkpoint inhibitor (ICI)-induced …

Abstract Purpose Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy
but can lead to GI toxicity, termed immune-mediated diarrhea and colitis (IMDC) …

Immune checkpoint inhibitors (ICI) have transformed the management of cancer, producing
durable responses in a subset of treated patients across multiple malignancies. Immune …

Introduction The use of immune checkpoint inhibitors (ICIs) in cancer immunotherapy has
shown increased overall survival in a wide range of cancer types with the associated risk of …